Investigating how HIV-1 Vpr affects gene expression and cell cycle control
Host protein targets of HIV-1 Vpr in gene expression, cell cycle and innate immunity
This study is looking at how a protein made by HIV-1, called Vpr, affects the way our cells work and helps the virus grow, by focusing on another protein called CCDC137, which might play a role in how HIV-1 behaves in our bodies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10898735 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a viral protein called Vpr, which is produced by HIV-1. Vpr is known to disrupt the normal cell cycle and enhance the virus's ability to replicate by targeting specific host proteins for degradation. The study aims to explore how a particular host protein, CCDC137, is involved in regulating HIV-1 gene expression and how it influences the cell cycle and DNA damage response. By examining the interactions between Vpr and CCDC137, researchers hope to uncover new insights into the mechanisms of HIV-1 infection and its effects on host cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who may benefit from advancements in treatment strategies.
Not a fit: Patients who are not infected with HIV-1 or those with other unrelated health conditions may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating HIV-1 infections by targeting the mechanisms that the virus uses to manipulate host cell functions.
How similar studies have performed: Previous research has shown success in understanding viral mechanisms similar to those being investigated in this study, indicating a promising avenue for further exploration.
Where this research is happening
New York, United States
- Rockefeller University — New York, United States (Active)
Researchers
- Principal investigator: Bieniasz, Paul D. — Rockefeller University
- Study coordinator: Bieniasz, Paul D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.